top of page
Asset 1_250.png

Replace, reduce, and refine animal use with modernized preclinical drug testing

A new model of drug testing leveraging primate stem cells to ensure predictability and reduce animal use

SOT logo black and white.jpg

At the March 2024 Society of Toxicology (SOT) meeting, Exir Bio presented how it is changing the way the industry handles primate use for drug efficacy and safety testing.  

If you missed the presentation, you can still receive it here!

Bridging the gap between human and mouse

Exir Bio's proprietary technology uses primate stem cells to create reproducible, ethical, and clinically relevant preclinical testing solutions.

Image by Drew Hays

Cost-Effective

Mitigate rising costs of monkey acquisition with stem-cell-based preclinical drug candidate screening

Consistent

Eliminate genetic variation between samples to ensure test result reproducibility

Image by National Cancer Institute
Image by Ivars Utināns

Conscientious

Improve research ethics by replacing, reducing, and refining the use of animals

Building the future of biomedical research

At Exir, we're transforming drug development by matching primate stem cells with their personalized genomes for cell and gene therapy. Combining in vitro and in vivo models, we speed discovery and preclinical workflows prior to human trials.

13x

increase in per-monkey acquisition cost since 2019

Monkey Cost.png

“Attitudes towards experimenting on monkeys are diverging. Many countries are growing warier, even as China races ahead.”

economist.png
The Economist, July 2021

Interested in Exir Bio?

© 2024 Exir Bio. All Rights Reserved.
bottom of page